Lung cancer: A phase I trial exists that studies six patients with stage IIIB-IV non-small-cell lung cancer (NSCLC) treated with PD-1 KO anti-MUC-1 CAR T cells [255]. The gene discussed is MUC1; the disease is lung cancer.